Evidence map›Paper›PMID 38356030›Full record

ArticleMolecular biology reports2024

Antifibrotic effect of silymarin on arecoline-induced fibrosis in primary human buccal fibroblasts: an in silico and in vitro analysis.

Divyambika Catakapatri Venugopal, Paramesh Viswanathan, Soundharya Ravindran, Alan Mathew Punnoose, Madhavan Yasasve, Davis G Dicky John, Lavanya Prabhakar, Gnanasambandan Ramanathan, Sathasivasubramanian Sankarapandian, Vijayalakshmi Ramshankar

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Divyambika Catakapatri VenugopalDepartment of Oral Medicine and Radiology, Sri Ramachandra Dental College & Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600 116, India. cvdivyambika@sriramachandra.edu.in.
Paramesh ViswanathanStem Cell & Regenerative Biology Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education & Research (DU), Porur, Chennai, 600 116, India.
Soundharya RavindranDepartment of Preventive Oncology (Research), Cancer Institute (WIA), Adyar, Chennai, 600020, India.
Alan Mathew PunnooseStem Cell & Regenerative Biology Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education & Research (DU), Porur, Chennai, 600 116, India.
Madhavan YasasveDepartment of Oral Medicine and Radiology, Sri Ramachandra Dental College & Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600 116, India.
Davis G Dicky JohnDepartment of Bioinformatics, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600 116, India.
Lavanya PrabhakarDepartment of Bioinformatics, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600 116, India.
Gnanasambandan RamanathanDepartment of Biomedical Science, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, 632 014, India.
Sathasivasubramanian SankarapandianDepartment of Oral Medicine and Radiology, Sri Ramachandra Dental College & Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, 600 116, India.
Vijayalakshmi RamshankarDepartment of Preventive Oncology (Research), Cancer Institute (WIA), Adyar, Chennai, 600020, India. r.vijayalakshmi@cancerinstitutewia.org.
Sri Ramachandra Institute of Higher Education and Research · INCancer Institute (WIA) · INVellore Institute of Technology University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to assess silymarin's anticancer and antifibrotic potential through in silico analysis and investigate its impact on in vitro arecoline-induced fibrosis in primary human buccal fibroblasts (HBF). METHODS &

resultsThe study utilized iGEMDOCK for molecular docking, evaluating nine bioflavonoids, and identified silymarin and baicalein as the top two compounds with the highest target affinity, followed by subsequent validation through a 100ns Molecular Dynamic Simulation demonstrating silymarin's stable behavior with Transforming Growth Factor Beta. HBF cell lines were developed from tissue samples obtained from patients undergoing third molar extraction. Arecoline, a known etiological factor in oral submucous fibrosis (OSMF), was employed to induce fibrogenesis in these HBFs. The inhibitory concentration (IC

conclusionSilymarin effectively inhibited fibroblast proliferation and downregulated genes associated with cancer progression and EMT pathway, both of which are implicated in malignant transformation. To our knowledge, this study represents the first exploration of silymarin's potential as a novel therapeutic agent in an in vitro model of OSMF.

Indexed as

ArecolineOral Submucous FibrosisFibroblastsFibrosisHumansMolecular Docking SimulationMouth MucosaArecolineArecolineCell cultureFibrosisGene expressionOSMFSilymarin

Identifiers

PMID38356030
OpenAlexW4391841902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.